Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -1753.94x is 189% below its 5-year average of -607.56x, near the high end of its 5-year range (-7891.50x–-10.63x).
53.66% above its 12-month average of -3784.72x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -7891.50x.
INTEREST COVERAGE RATIO
-1753.94x
INTEREST COVERAGE RATIO AVG TTM
-3784.72x
INTEREST COVERAGE RATIO AVG 3Y
-999.12x
INTEREST COVERAGE RATIO AVG 5Y
-607.56x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+53.66%
CURRENT VS 3Y AVG
-75.55%
CURRENT VS 5Y AVG
-188.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
-27412.78%
vs the sector median at left
Taysha Gene Therapies, Inc.
Market Cap
$1.40B
Interest Coverage Ratio
-1753.94x
TTM Avg
-3784.72x
3Y Avg
-999.12x
5Y Avg
-607.56x
Market Cap
$1.40B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Interest Coverage Ratio
0.60x
TTM Avg
0.60x
3Y Avg
0.60x
5Y Avg
0.60x
Market Cap
$1.39B
Interest Coverage Ratio
7.70x
TTM Avg
6.59x
3Y Avg
5.19x
5Y Avg
6.41x
Market Cap
$1.42B
Interest Coverage Ratio
-8.63x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.37B
Interest Coverage Ratio
-11.07x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
Interest Coverage Ratio
1.06x
TTM Avg
1.06x
3Y Avg
1.45x
5Y Avg
1.23x
Market Cap
$1.45B
Interest Coverage Ratio
30.72x
TTM Avg
19.49x
3Y Avg
15.15x
5Y Avg
21.38x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.40B | -1753.94x | -3784.72x | -999.12x | -607.56x |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 0.60x | 0.60x | 0.60x | 0.60x |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 7.70x | 6.59x | 5.19x | 6.41x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -8.63x | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -11.07x | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | 1.06x | 1.06x | 1.45x | 1.23x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 30.72x | 19.49x | 15.15x | 21.38x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | N/A | N/A | N/A |
Interest Coverage
-1753.9x
Debt/Equity
0.14
Current Ratio
17.76
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -7891.50x |
| 2026-03-31 | -4831.78x |
| 2025-12-31 | -2358.33x |
| 2025-09-30 | -2268.27x |
| 2025-06-30 | -1573.71x |
| 2025-03-31 | -1127.42x |
| 2024-12-31 | -906.00x |
| 2024-09-30 | -1079.08x |
| 2024-06-30 | -788.85x |
| 2024-03-31 | -838.97x |
| 2023-12-31 | -22.79x |
| 2023-09-30 | -10.63x |
| 2023-06-30 | -16.24x |
| 2023-03-31 | -12.05x |
| 2022-12-31 | -23.49x |
| 2022-09-30 | -23.62x |
| 2022-06-30 | -44.92x |
| 2022-03-31 | -73.89x |
| 2021-12-31 | -71.96x |
| 2021-09-30 | -93.34x |
| 2021-06-30 | -210.16x |
| 2020-09-30 | -15041.00x |
| 2020-03-31 | -206.81x |
